Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737515 | 0.82 | HSD17B10 (0.42) | — | |
| SCHEMBL6314664 | 0.75 | POLB (0.33) | — | |
| SCHEMBL15332756 | 0.73 | TTR (0.33) | — | |
| SCHEMBL28700312 | 0.71 | DRD2 (0.32) | — | |
| SCHEMBL23192881 | 0.71 | DHFR (0.44) | — | |
| SCHEMBL9128937 | 0.70 | THRB (0.37) | — | |
| SCHEMBL2497862 | 0.70 | APLNR (0.46) | APLNR | |
| SCHEMBL3242496 | 0.70 | CYP1A2 (0.37) | — | |
| SCHEMBL31073192 | 0.69 | APLNR (0.42) | APLNR | |
| SCHEMBL31042359 | 0.69 | APLNR (0.42) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138340-B2 | Bicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-20 | — | — | US | disclosed |
| EP-1786814-B1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20090306123-A1 | Bicyclononene derivaties | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
| EP-2029542-A2 | PRIMARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007099509-A2 | PRIMARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | APLNR 1891/4885 |
| US-20090306123-A1 | Bicyclononene derivaties | REN, ACE, CYP51A1 | APLNR 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.